Position in FATE
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$26,916
+$12,536 QoQ
Shares Held
22,430
+52.9% QoQ
Ownership
0.019%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 36.91038787338386.ToString("F0")%
Shared 0.ToString("F0")%
None 63.08961212661613.ToString("F0")%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pallas Capital Advisors LLC holds $23,981,428 across 32 Biotechnology names. FATE ranks #28 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
40,610 | $6,863,902 | |
| 2 | RPRX |
Royalty Pharma plc
|
102,969 | $4,939,422 | |
| 3 | INCY |
Incyte Corp
|
33,157 | $3,120,736 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,680 | $2,070,675 | |
| 5 | EXEL |
Exelixis, Inc.
|
29,215 | $1,253,031 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,212 | $731,884 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,638 | $731,432 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
12,396 | $700,250 |
All Filings in FATE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,916 | 22,430 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $14,380 | 14,674 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $21,116 | 16,759 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $17,176 | 15,336 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $11,243 | 14,232 | Shares | Sole | 2025-04-14 | |
| No filing history on record for this holder in this stock. | ||||||